https://www.selleckchem.com/products/AZD0530.html
.8%; 95% CI, 0.2% to 2.2%). No SAE was associated with vaccination. Changes in prevaccination and postvaccination HRQOL scores were not clinically meaningful and not different between the groups. Overall safety and HRQOL findings were similar after aIIV3 and HD-IIV3, and consistent with prelicensure data. From a safety standpoint, this study's results support using either vaccine to prevent influenza in older adults. ClinicalTrials.gov Identifier NCT03183908. ClinicalTrials.gov Identifier NCT03183908.Few large cohorts have examined hist
Like
Comment
Share
